Tianjin Medical University Cancer Institute & Hospital

New Impact Factor of Cancer Biology & Medicine: 5.5

According to 2022 Journal Citation Reports, the NEW IMPACT FACTOR (2022) of Cancer Biology & Medicine (CBM) is 5.5 (5-year IF=6.1), locating in Q2 area both in Medicine, Research & Experimental category (ranking 38/136) and Oncology category (ranking 68/241).

As a peer-reviewed open-access journal, Cancer Biology & Medicine (CBM) is published by China Anti-Cancer Association and Tianjin Medical University Cancer Institute & Hospital. It focuses on translational cancer research, dedicating to narrowing the gap between bench and bedside. CBM strictly adheres to guidelines of the International Committee of Medical Journal Editors (ICMJE), and Committee on Publication Ethics (COPE). The journal is now indexed in Science Citation Index Expanded and MEDLINE.

Welcome to submit your work to Cancer Biology & Medicine and communicate with your colleagues worldwide via our platform.

Journal web: http://www.cancerbiomed.org

Full text in PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/journals/2000/

Online submission: https://mc03.manuscriptcentral.com/cbm